JP2025160215A5 - - Google Patents

Info

Publication number
JP2025160215A5
JP2025160215A5 JP2025113503A JP2025113503A JP2025160215A5 JP 2025160215 A5 JP2025160215 A5 JP 2025160215A5 JP 2025113503 A JP2025113503 A JP 2025113503A JP 2025113503 A JP2025113503 A JP 2025113503A JP 2025160215 A5 JP2025160215 A5 JP 2025160215A5
Authority
JP
Japan
Prior art keywords
antibody
disease
adc
syndrome
autoimmune
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2025113503A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025160215A (ja
Filing date
Publication date
Priority claimed from JP2021518969A external-priority patent/JP7709376B2/ja
Application filed filed Critical
Publication of JP2025160215A publication Critical patent/JP2025160215A/ja
Publication of JP2025160215A5 publication Critical patent/JP2025160215A5/ja
Pending legal-status Critical Current

Links

JP2025113503A 2018-10-23 2025-07-04 Fcサイレンス化抗体薬物コンジュゲート(ADC)及びその使用 Pending JP2025160215A (ja)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201862749662P 2018-10-23 2018-10-23
US62/749,662 2018-10-23
US201862773839P 2018-11-30 2018-11-30
US62/773,839 2018-11-30
US201962807363P 2019-02-19 2019-02-19
US62/807,363 2019-02-19
JP2021518969A JP7709376B2 (ja) 2018-10-23 2019-10-23 Fcサイレンス化抗体薬物コンジュゲート(ADC)及びその使用
PCT/US2019/057741 WO2020086776A1 (en) 2018-10-23 2019-10-23 Fc silenced antibody drug conjugates (adcs) and uses thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2021518969A Division JP7709376B2 (ja) 2018-10-23 2019-10-23 Fcサイレンス化抗体薬物コンジュゲート(ADC)及びその使用

Publications (2)

Publication Number Publication Date
JP2025160215A JP2025160215A (ja) 2025-10-22
JP2025160215A5 true JP2025160215A5 (cg-RX-API-DMAC7.html) 2026-01-22

Family

ID=70331253

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021518969A Active JP7709376B2 (ja) 2018-10-23 2019-10-23 Fcサイレンス化抗体薬物コンジュゲート(ADC)及びその使用
JP2025113503A Pending JP2025160215A (ja) 2018-10-23 2025-07-04 Fcサイレンス化抗体薬物コンジュゲート(ADC)及びその使用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2021518969A Active JP7709376B2 (ja) 2018-10-23 2019-10-23 Fcサイレンス化抗体薬物コンジュゲート(ADC)及びその使用

Country Status (12)

Country Link
US (1) US20200255523A1 (cg-RX-API-DMAC7.html)
EP (1) EP3873930A4 (cg-RX-API-DMAC7.html)
JP (2) JP7709376B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210081393A (cg-RX-API-DMAC7.html)
CN (1) CN113330026A (cg-RX-API-DMAC7.html)
BR (1) BR112021007555A2 (cg-RX-API-DMAC7.html)
CA (1) CA3115680A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021006259A2 (cg-RX-API-DMAC7.html)
IL (1) IL282292B1 (cg-RX-API-DMAC7.html)
MX (1) MX2021004231A (cg-RX-API-DMAC7.html)
SG (1) SG11202103568PA (cg-RX-API-DMAC7.html)
WO (1) WO2020086776A1 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019217942A1 (en) 2018-05-11 2019-11-14 Beam Therapeutics Inc. Methods of substituting pathogenic amino acids using programmable base editor systems
US20200376135A1 (en) * 2018-10-23 2020-12-03 Magenta Therapeutics, Inc. Fc silenced antibody drug conjugates (adcs) and uses thereof
AU2019370367A1 (en) 2018-10-30 2021-06-17 Magenta Therapeutics, Inc. Anti-CD45 antibodies and conjugates thereof
EP3958878A4 (en) * 2019-04-24 2022-12-28 Magenta Therapeutics, Inc. CONDITIONING METHODS FOR GENE THERAPY
WO2020219778A2 (en) * 2019-04-24 2020-10-29 Magenta Therapeutics, Inc. Anti-cd117 antibody-drug conjugates and uses thereof
JP2022530442A (ja) * 2019-04-24 2022-06-29 マジェンタ セラピューティクス インコーポレイテッド アントラサイクリン抗体薬物複合体およびその使用
AU2020376934A1 (en) 2019-11-01 2022-06-02 Regeneron Pharmaceuticals, Inc. Anti-CD45 antibodies and conjugates thereof
EP4121462A4 (en) * 2020-03-16 2024-04-24 Magenta Therapeutics, Inc. BISPECIFIC T CELL BINDING PROTEINS
GB2595299B (en) 2020-05-21 2022-08-03 Mabsolve Ltd Modified immunoglobulin FC regions
EP4161946A1 (en) 2020-06-09 2023-04-12 Heidelberg Pharma Research GmbH Method for synthesis of thioether-containing peptides
WO2021255217A1 (en) 2020-06-19 2021-12-23 Heidelberg Pharma Research Gmbh Amatoxin and amatoxin conjugates for use in inhibition of rna virus replication
KR102594083B1 (ko) 2020-07-07 2023-10-25 칸큐어 엘엘씨 Mic 항체 및 결합제 및 이의 사용 방법
KR20250054799A (ko) 2022-08-29 2025-04-23 다이이찌 산쿄 가부시키가이샤 변이 Fc 영역을 포함하는 항체 약물 콘쥬게이트
WO2024121632A1 (en) * 2022-12-09 2024-06-13 Crispr Therapeutics Ag Use of anti-cd117 antibody drug conjugate (adc)
WO2024258967A1 (en) * 2023-06-13 2024-12-19 Synthis Therapeutics, Inc. Anti-cd5 antibodies and their uses
KR20250065477A (ko) * 2023-11-03 2025-05-13 고려대학교 산학협력단 작용기 기능이 제거된 Fab-arm 교환 방지 Fc 변이체들
WO2025099280A1 (en) * 2023-11-08 2025-05-15 Oxion Biologics Ab Improved anti-ox40l antibodies
WO2026014615A1 (ko) * 2024-07-10 2026-01-15 고려대학교 산학협력단 작용기 기능이 제거된 신규 당화 fc 변이체

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040875A1 (en) * 1995-06-07 1996-12-19 Novartis Ag Methods for obtaining compositions enriched for hematopoietic stem cells and antibodies for use therein
US7435596B2 (en) * 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
PL2099823T5 (pl) * 2006-12-01 2023-02-20 Seagen Inc. Wariant środków wiążących cel i jego zastosowania
EP2625203A1 (en) * 2010-10-05 2013-08-14 Novartis AG Anti-il12rbeta1 antibodies and their use in treating autoimmune and inflammatory disorders
TWI736437B (zh) * 2010-11-30 2021-08-11 日商中外製藥股份有限公司 細胞傷害誘導治療劑
PL2723773T3 (pl) * 2011-06-22 2018-07-31 F.Hoffmann-La Roche Ag Eliminacja komórek docelowych przez obecne w krążeniu, swoiste dla wirusa, cytotoksyczne limfocyty T z wykorzystaniem kompleksów zawierających MHC klasy I
WO2014006217A1 (en) * 2012-07-06 2014-01-09 Genmab B.V. Dimeric protein with triple mutations
BR112015000798A2 (pt) * 2012-07-13 2017-06-27 Zymeworks Inc heterodímeros assimétricos biespecíficos compreendendo construtos anti-cd3
CA2876096A1 (en) * 2012-08-02 2014-02-06 Petra Rueger Method for producing soluble fcr as fc-fusion with inert immunoglobulin fc-region and uses thereof
EP3004174B1 (en) * 2013-05-31 2019-04-17 Zymeworks Inc. Heteromultimers with reduced or silenced effector function
ES2826566T3 (es) * 2014-11-21 2021-05-18 Bristol Myers Squibb Co Anticuerpos que comprenden regiones constantes pesadas modificadas
DK3268047T3 (da) * 2015-03-09 2024-01-02 Heidelberg Pharma Res Gmbh Amatoxin/antistof-konjugater
JP7725185B2 (ja) * 2015-10-06 2025-08-19 アレクトル エルエルシー 抗trem2抗体及びその使用方法
MA43389A (fr) * 2015-12-02 2021-05-12 Agenus Inc Anticorps anti-ox40 et leurs procédés d'utilisation
KR20180087430A (ko) * 2015-12-17 2018-08-01 얀센 바이오테크 인코포레이티드 Hla-dr에 특이적으로 결합하는 항체 및 이의 용도
WO2017157948A1 (en) * 2016-03-14 2017-09-21 Innate Pharma Anti-cd39 antibodies
KR102692708B1 (ko) * 2016-12-20 2024-08-07 에프. 호프만-라 로슈 아게 항-cd20/항-cd3 이중특이성 항체 및 4-1bb(cd137) 작용물질의 병용 요법
CN117653740A (zh) * 2016-12-21 2024-03-08 诺华股份有限公司 用于消融造血干细胞的抗体药物缀合物
BR112019012937A2 (pt) * 2016-12-23 2019-12-10 Heidelberg Pharma Research Gmbh novo conjugado de amanitina
WO2019082821A1 (ja) * 2017-10-24 2019-05-02 日本碍子株式会社 ウエハ載置台及びその製法
US10882915B2 (en) * 2017-10-24 2021-01-05 Magenta Therapeutics, Inc. Compositions and methods for the depletion of CD117+ cells
WO2020219778A2 (en) * 2019-04-24 2020-10-29 Magenta Therapeutics, Inc. Anti-cd117 antibody-drug conjugates and uses thereof
JP2022530442A (ja) * 2019-04-24 2022-06-29 マジェンタ セラピューティクス インコーポレイテッド アントラサイクリン抗体薬物複合体およびその使用
JP2022530438A (ja) * 2019-04-24 2022-06-29 マジェンタ セラピューティクス インコーポレイテッド 抗cd117抗体薬物複合体およびその使用
WO2020216947A1 (en) * 2019-04-24 2020-10-29 Heidelberg Pharma Research Gmbh Amatoxin antibody-drug conjugates and uses thereof
EP3958878A4 (en) * 2019-04-24 2022-12-28 Magenta Therapeutics, Inc. CONDITIONING METHODS FOR GENE THERAPY
CN118131538A (zh) * 2022-12-02 2024-06-04 群创光电股份有限公司 电子装置

Similar Documents

Publication Publication Date Title
JP2022512629A5 (cg-RX-API-DMAC7.html)
JP2022553839A5 (cg-RX-API-DMAC7.html)
JP7791923B2 (ja) Cd5+細胞の枯渇のための組成物および方法
US20240408168A1 (en) Compositions and methods for the depletion of cells
JP7472210B2 (ja) 有効性の改善および毒性の減少のための、抗体およびsn-38からなるイムノコンジュゲートの投薬
JP7650819B2 (ja) 抗-cd45抗体薬物コンジュゲート及びその使用
US12533419B2 (en) Antibody drug conjugate loaded with binary toxins and its application
JP6828950B2 (ja) Cl2aリンカーを有する抗体−sn−38免疫抱合体
JP2021500391A5 (cg-RX-API-DMAC7.html)
ES2845924T3 (es) Interruptores de células T con receptores de antígenos quiméricos peptídicos y usos de los mismos
ES2931923T3 (es) Inmunoconjugados con una enlace intracelularmente escindible
WO2019084064A4 (en) Compositions and methods for the depletion of cd117+ cells
US20260102505A1 (en) Anti-cd45-ign antibody drug conjugates and uses thereof
JP2016534092A (ja) Cl2aリンカーを有する抗体−sn−38免疫複合体
US20240254251A1 (en) Anti-cd45 antibodies and conjugates thereof
JP2018531026A (ja) T細胞療法用のt細胞を調製する方法
JP2020504112A5 (cg-RX-API-DMAC7.html)
JP2022531141A5 (cg-RX-API-DMAC7.html)
US20220177577A1 (en) Anti-cd117 antibody drug conjugates and uses thereof
US20220226493A1 (en) Anthracycline antibody-drug conjugates and uses thereof
Offidani et al. Novel experimental drugs for treatment of multiple myeloma
CN117157098A (zh) 一种药物组合及其用途
WO2019108860A4 (en) Compositions and methods for the depletion of cd2+ cells
JP2021505172A5 (cg-RX-API-DMAC7.html)
AU2024355542A1 (en) Constrained ionizable cationic lipids and lipid nanoparticles